Form 8-K - Current report:
SEC Accession No. 0001493152-21-024376
Filing Date
2021-10-01
Accepted
2021-10-01 17:19:21
Documents
14
Period of Report
2021-09-29
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 57099
2 ex3-1.htm EX-3.1 12031
  Complete submission text file 0001493152-21-024376.txt   291204

Data Files

Seq Description Document Type Size
3 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ptix-20210929.xsd EX-101.SCH 3519
4 INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT ptix-20210929_def.xml EX-101.DEF 26583
5 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ptix-20210929_lab.xml EX-101.LAB 36525
6 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ptix-20210929_pre.xml EX-101.PRE 25201
7 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5339
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 (212) 994-8200
Protagenic Therapeutics, Inc.\new (Filer) CIK: 0001022899 (see all company filings)

EIN.: 061390025 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12555 | Film No.: 211299992
SIC: 7389 Services-Business Services, NEC